| Literature DB >> 32163431 |
Suzette Glasner1,2, Helene Chokron Garneau1, Alfonso Ang1, Lara Ray3, Alexandra Venegas1,3, Richard Rawson1,4, Seth Kalichman5.
Abstract
TRIAL REGISTRATION: This trial was registered with ClinicalTrials.gov, NCT02603471.Entities:
Year: 2020 PMID: 32163431 PMCID: PMC7067560 DOI: 10.1371/journal.pone.0229557
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1CONSORT flow diagram.
Sample characteristics.
| Sample N = 35 | TXT-CBT N = 17 | Control N = 18 | |
|---|---|---|---|
| Age, M (SD) | 50.2 (10.2) | 47.6 (11.5) | 52.7 (6.1) |
| Gender, N (%) | |||
| Male | 30 (85.7) | 16 (53.3) | 14 (46.7) |
| Female | 5 (14.3) | 1 (20.0) | 4 (80.0) |
| Yrs Education, M (SD) | 12.4 (3.1) | 11.8 (1.8) | 12.9 (3.9) |
| Race, N (%) | |||
| White | 5 (14.3) | 1 (20.0) | 4 (80.0) |
| African-American | 21 (60.0) | 11 (55.6) | 10 (55.6) |
| Hispanic | 9 (25.7) | 5 (55.6) | 4 (45.4) |
| Employment, N (%) | |||
| Full time | 6 (17.1) | 2 (33.3) | 4 (57.1) |
| Part time | 4 (11.4) | 2 (50.0) | 2 (50.0) |
| Retired/disabled | 20 (57.2) | 11 (55.0) | 9 (45.0) |
| Unemployed | 5 (14.3) | 2 (40.0) | 3 (60.0) |
| Marital status, N (%) | |||
| Legally married/Living with partner | 4 11.8) | 3 (75.0) | 1 (25.0) |
| Separated/Divorced/Widowed | 12 (35.3) | 6 (50.0) | 6 (50.0) |
| Never married | 18 (52.9) | 8 (44.4) | 10 (55.6) |
| Alcohol Use (past 30 days) | |||
| Days of alcohol use, M (sd) | 13.1 (10.5) | 11.8 (9.7) | 14.3 (11.4) |
| Drinking to intoxication days M (sd) | 6.7 (8.6) | 4.8 (6.5) | 8.5 (10.0) |
The majority of participants in the ALC-TXT-CBT condition (n = 11; 65%) opted to receive 2 text messages daily in addition to medication reminders, with the remainder having selected 3 daily messages. In terms of usage of optional features, the text CRAVE option was utilized once, and the LIFELINE and CALL options were not utilized.
Fig 2Alcohol use frequency (past 30 days) from baseline to week 12 by treatment group.
Fig 3Mean days of alcohol intoxication (past 30 days) from baseline to week 12 by treatment group.
Fig 4Mean ART adherence scores at weeks 0, 4, 8, and 12 by treatment group.
Fig 5Mean log viral load levels as a function of treatment group at baseline and week 12.